New treatment for lymphedema using targeted drug delivery
Lymphedema therapy via lymphatic targeted drug delivery
This study is exploring a new way to help people with lymphedema, a condition that causes swelling from fluid buildup, by testing a special method to deliver treatments directly to the lymphatic system, which could make managing the condition easier and more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11064076 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat lymphedema, a condition often resulting from cancer treatments that leads to fluid buildup and swelling. The study aims to develop a targeted drug delivery system that can effectively deliver therapies directly to the lymphatic system, potentially improving treatment outcomes. Using pre-clinical models that mimic human lymphedema, the research will test various drug combinations to reduce inflammation and improve lymphatic function. This approach seeks to address the chronic nature of lymphedema, which currently has no cure.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer survivors who have developed lymphedema as a result of their treatment.
Not a fit: Patients who do not have lymphedema or those with lymphedema caused by factors unrelated to cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from lymphedema, significantly improving their quality of life.
How similar studies have performed: While the approach of targeted drug delivery is being explored in various contexts, this specific application for lymphedema treatment is relatively novel and has not been extensively tested.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Thomas, Susan Napier — Georgia Institute of Technology
- Study coordinator: Thomas, Susan Napier
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.